|Bid||62.93 x 1200|
|Ask||63.43 x 4000|
|Day's Range||62.38 - 66.10|
|52 Week Range||37.68 - 87.29|
|Beta (5Y Monthly)||1.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
KrystalBiotech shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Krystal Biotech Inc (NASDAQ: KRYS) has priced the previously announced underwritten public offering of 1.923 million common shares at $65/share, representing gross proceeds of $125 million. Underwriters having an option to purchase up to an additional 288 thousand shares. Net proceeds from this offering together with its existing cash, cash equivalents, and short-term investments will be used to complete the ongoing pivotal trial of B-VEC for DEB and prepare for potential commercialization, advance the development of KB105 in TGM1-deficient ichthyosis, preclinical development of KB104 for Netherton syndrome, advance development of KB407 for cystic fibrosis, accelerate the Company's emerging respiratory pipeline, as well as for working capital and general corporate purposes. The offering is expected to close by February 5. KRYS shares are down 5.48% at $67.04 in the pre-market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaAmgen Shares Dip On Light 2021 Outlook, Paused StudiesEli Lilly, Innovent Biologics' Sintilimab Injection Receives China Approval For A Type Of Lung Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.